EP1578945A4 - Cct6 utilises comme modificateurs de la voie rb, et procedes d'utilisation correspondants - Google Patents

Cct6 utilises comme modificateurs de la voie rb, et procedes d'utilisation correspondants

Info

Publication number
EP1578945A4
EP1578945A4 EP03789986A EP03789986A EP1578945A4 EP 1578945 A4 EP1578945 A4 EP 1578945A4 EP 03789986 A EP03789986 A EP 03789986A EP 03789986 A EP03789986 A EP 03789986A EP 1578945 A4 EP1578945 A4 EP 1578945A4
Authority
EP
European Patent Office
Prior art keywords
cct6s
modifiers
pathway
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03789986A
Other languages
German (de)
English (en)
Other versions
EP1578945A3 (fr
EP1578945A2 (fr
Inventor
Albert K Tai
Chunyan Song
Michael Martin Ollmann
Lucile A Gillett
Kim Lickteig
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exelixis Inc
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of EP1578945A3 publication Critical patent/EP1578945A3/fr
Publication of EP1578945A2 publication Critical patent/EP1578945A2/fr
Publication of EP1578945A4 publication Critical patent/EP1578945A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
EP03789986A 2002-11-25 2003-11-24 Cct6 utilises comme modificateurs de la voie rb, et procedes d'utilisation correspondants Withdrawn EP1578945A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42887202P 2002-11-25 2002-11-25
US428872P 2002-11-25
PCT/US2003/037548 WO2004048541A2 (fr) 2002-11-25 2003-11-24 Cct6 utilises comme modificateurs de la voie rb, et procedes d'utilisation correspondants

Publications (3)

Publication Number Publication Date
EP1578945A3 EP1578945A3 (fr) 2005-08-18
EP1578945A2 EP1578945A2 (fr) 2005-09-28
EP1578945A4 true EP1578945A4 (fr) 2006-09-27

Family

ID=32393472

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03789986A Withdrawn EP1578945A4 (fr) 2002-11-25 2003-11-24 Cct6 utilises comme modificateurs de la voie rb, et procedes d'utilisation correspondants

Country Status (5)

Country Link
EP (1) EP1578945A4 (fr)
JP (1) JP4646631B2 (fr)
AU (2) AU2003294501B2 (fr)
CA (1) CA2506686A1 (fr)
WO (2) WO2004048536A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8263403B2 (en) 2007-04-23 2012-09-11 Stowers Institute For Medical Research Methods and compositions for stem cell self-renewal

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997041433A1 (fr) * 1996-04-29 1997-11-06 Cancer Research Campaign Technology Limited METHODES ET MOYENS D'INTERRUPTION DE L'INTERACTION p53/RB
WO1999041376A2 (fr) * 1998-02-12 1999-08-19 Curagen Corporation Complexes proteiques de retinoblastome et proteines interagissant avec le retinoblastome
US6071715A (en) * 1993-08-12 2000-06-06 Board Of Regents, The University Of Texas System Nucleic acids encoding novel proteins which bind to retinoblastoma protein

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6071715A (en) * 1993-08-12 2000-06-06 Board Of Regents, The University Of Texas System Nucleic acids encoding novel proteins which bind to retinoblastoma protein
WO1997041433A1 (fr) * 1996-04-29 1997-11-06 Cancer Research Campaign Technology Limited METHODES ET MOYENS D'INTERRUPTION DE L'INTERACTION p53/RB
WO1999041376A2 (fr) * 1998-02-12 1999-08-19 Curagen Corporation Complexes proteiques de retinoblastome et proteines interagissant avec le retinoblastome

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DECAPRIO ET AL: "The Product of the Retinoblastoma Susceptibility Gene Has Properties of a Cell Cycle Regulatory Element", CELL, vol. 58, pages 1085 - 1095, XP008087857 *
FELDMAN DOUGLAS E ET AL: "Formation of the VHL-elongin BC tumor suppressor complex is mediated by the chaperonin TRiC", MOLECULAR CELL, vol. 4, no. 6, December 1999 (1999-12-01), pages 1051 - 1061, XP002394305, ISSN: 1097-2765 *
KUBOTA HIROSHI ET AL: "Structures and co-regulated expression of the genes encoding mouse cytosolic chaperonin CCT subunits", EUROPEAN JOURNAL OF BIOCHEMISTRY, vol. 262, no. 2, June 1999 (1999-06-01), pages 492 - 500, XP002394304, ISSN: 0014-2956 *
LI WEN-ZHUO ET AL: "Tcp20, a subunit of the eukaryotic TRiC chaperonin from humans and yeast", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 269, no. 28, 1994, pages 18616 - 18622, XP002394303, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
WO2004048536A3 (fr) 2004-08-19
CA2506686A1 (fr) 2004-06-10
AU2003294499A8 (en) 2004-06-18
WO2004048536A2 (fr) 2004-06-10
AU2003294501A1 (en) 2004-06-18
WO2004048541A2 (fr) 2004-06-10
WO2004048541A3 (fr) 2005-08-18
AU2003294499A1 (en) 2004-06-18
JP2006507005A (ja) 2006-03-02
AU2003294501B2 (en) 2010-05-13
EP1578945A2 (fr) 2005-09-28
JP4646631B2 (ja) 2011-03-09

Similar Documents

Publication Publication Date Title
AU2003224638A8 (en) Pdpk1s as modifiers of the p53 pathway and methods of use
EP1401475A4 (fr) Prmt comme modificateurs de la voie p53 et methodes d'utilisation
EP1421384A4 (fr) Hprp4 en tant que modificateurs de la voie de passage p53 leurs et methodes d'utilisation
EP1651956A4 (fr) Melks utilises comme modificateurs du mecanisme d'action de rac et procedes d'utilisation
AU2003272390A8 (en) Ampds as modifiers of the p21 pathway and methods of use
EP1535067A4 (fr) Papss comme modificateurs de la voie d'axin et procedes d'utilisation
AU2003274911A8 (en) Mrbs as modifiers of the rb pathway and methods of use
AU2003295881A8 (en) Lamps as modifiers of the p53 pathway and methods of use
AU2003294499A8 (en) Rhebs as modifiers of the rb pathway and methods of use
AU2003251799A1 (en) Mchks as modifiers of the chk1 pathway and methods of use
AU2003303094A8 (en) Mat2as as modifiers of the p53 pathway and methods of use
AU2003251826A8 (en) Mp21s as modifiers of the p21 pathway and methods of use
EP1534852A4 (fr) Genes csnk1gs utilises en tant que modificateurs de la voie p21 et procede d'utilisation associe
EP1578945A3 (fr) Cct6 utilises comme modificateurs de la voie rb, et procedes d'utilisation correspondants
EP1587910A4 (fr) Genes facl utilises comme modificateurs de la voie du retinoblastome (rb) et technique d'utilisation
AU2003299990A8 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use
AU2003217851A8 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use
HK1080110A1 (zh) 作為chk通路調節子的paks及使用方法
AU2003213665A8 (en) Lgals as modifiers of the chk pathway and methods of use
AU2003213693A8 (en) Mchks as modifiers of the chk pathway and methods of use
AU2002361654A8 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use
AU2003278811A8 (en) Ldlrs as modifiers of the p53 pathway and methods of use
AU2003295928A8 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use
AU2003213662A8 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use
EP1540333A4 (fr) Max utilises comme modificateurs de la voie de l'axine et methodes d'utilisation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

PUAK Availability of information related to the publication of the international search report

Free format text: ORIGINAL CODE: 0009015

17P Request for examination filed

Effective date: 20050511

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 01N 61/00 B

Ipc: 7C 12Q 1/68 B

Ipc: 7G 01N 33/53 B

Ipc: 7G 01N 33/48 A

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 49/00 20060101ALI20060817BHEP

Ipc: C12Q 1/00 20060101AFI20060817BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20060830

RIN1 Information on inventor provided before grant (corrected)

Inventor name: LICKTEIG, KIM

Inventor name: GILLETT, LUCILE, A.

Inventor name: OLLMANN, MICHAEL, MARTIN

Inventor name: SONG, CHUNYAN

Inventor name: TAI, ALBERT, K.

17Q First examination report despatched

Effective date: 20070301

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120601